Recent progress in microneme-based vaccines development against Toxoplasma gondii
Clinical and Experimental Vaccine Research
; : 93-103, 2018.
Article
in En
| WPRIM
| ID: wpr-716060
Responsible library:
WPRO
ABSTRACT
Toxoplasmosis is a cosmopolitan zoonotic disease, which infect several warm-blooded mammals. More than one-third of the human population are seropositive worldwide. Due to the high seroprevalence of Toxoplasma gondii infection worldwide, the resulting clinical, mental, and economical complications, as well as incapability of current drugs in the elimination of parasites within tissue cysts, the development of a vaccine against T. gondii would be critical. In the past decades, valuable advances have been achieved in order to identification of vaccine candidates against T. gondii infection. Microneme proteins (MICs) secreted by the micronemes play a critical role in the initial stages of host cell invasion by parasites. In this review, we have summarized the recent progress for MIC-based vaccines development, such as DNA vaccines, recombinant protein vaccines, vaccines based on live-attenuated vectors, and prime-boost strategy in different mouse models. In conclusion, the use of live-attenuated vectors as vehicles to deliver and express the target gene and prime-boost regimens showed excellent outcomes in the development of vaccines against toxoplasmosis, which need more attention in the future studies.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Parasites
/
Toxoplasma
/
Vaccines
/
Zoonoses
/
Seroepidemiologic Studies
/
Toxoplasmosis
/
Vaccines, DNA
/
Mammals
Limits:
Animals
/
Humans
Language:
En
Journal:
Clinical and Experimental Vaccine Research
Year:
2018
Type:
Article